| Literature DB >> 27716310 |
Bandarn Suetrong1,2, Chawika Pisitsak1,3, John H Boyd1, James A Russell1, Keith R Walley4.
Abstract
BACKGROUND: Acute kidney injury and hyperchloremia are commonly present in critically ill septic patients. Our study goal was to evaluate the association of hyperchloremia and acute kidney injury in severe sepsis and septic shock patients.Entities:
Keywords: Acute kidney injury; Chloride; Hyperchloremia; Sepsis; Septic shock
Mesh:
Substances:
Year: 2016 PMID: 27716310 PMCID: PMC5053142 DOI: 10.1186/s13054-016-1499-7
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1Flow chart of the patients with severe sepsis and septic shock in the study. [Cl ] maximal chloride concentration in the first 48 hours, AKI acute kidney injury, CRF chronic renal failure
Demographic and clinical variables and outcome of patients classified by serum chloride status
| Variable | Hyperchloremia | No hyperchloremia |
|
|---|---|---|---|
| Demographics | |||
| Age, yr, mean ± SD | 57.5 ± 15.1 | 52.9 ± 18.4 | 0.05 |
| Male, % | 46.9 | 55.6 | 0.38 |
| Underlying diseases | |||
| Hypertension, % | 36.7 | 28.2 | 0.074 |
| Ischemic heart disease, % | 6.1 | 5.6 | 0.65 |
| CHF, % | 4.1 | 8.5 | 0.10 |
| DM, % | 21.4 | 21.1 | 0.71 |
| COPD, % | 21.4 | 18.3 | 0.086 |
| Cirrhosis, % | 7.1 | 4.9 | 0.082 |
| Malignancy, % | 4.1 | 5.6 | 0.20 |
| HIV, % | 11.2 | 9.2 | 0.56 |
| Chronic steroid treatment, % | 5.1 | 6.3 | 0.91 |
| Clinical parameters at presentation | |||
| MAP, mean ± SD | 85 ± 21 | 89 ± 17 | 0.12 |
| HR, mean ± SD | 104 ± 22 | 96 ± 21 | 0.003a |
| Lactate, mean ± SD | 2.9 ± 2.8 | 2.5 ± 2.4 | 0.29 |
| Creatinine(mg/dL), median (IQR) | 1.0 (0.7-1.4) | 0.9 (0.4-1.4) | 0.49 |
| APACHE II score, mean ± SD | 11.3 ± 5.0 | 7.8 ± 5.4 | <0.001a |
| Clinical parameters at 24 hr | |||
| Vasopressor, % | 31 | 11 | <0.001a |
| Mechanical ventilator, % | 64 | 32 | <0.001a |
| Fluid intake, mean ± SD | 4959 ± 3,417 | 4691 ± 2,341 | 0.71 |
| Urine output, mean ± SD | 2416 ± 1,146 | 2554 ± 1,463 | 0.644 |
| Chloride parameters | |||
| Initial chloride ([Cl-]0), mean ± SD | 104.3 ± 7.7 | 103.7 ± 4.6 | 0.51 |
| Maximal Cl in 48 hours ([Cl-]max) | 104.4 ± 3.7 | 114.4 ± 3.6 | <0.001a |
| Increase in serum Cl (Δ[Cl-]) | 3.2 ± 4.2 | 6.1 ± 5.0 | <0.001a |
| Clinical outcome | |||
| AKI, % | 85.7 | 47.9 | <0.001a |
| RRT, % | 7.1 | 3.5 | 0.206 |
| 28-day mortality, % | 6.1 | 1.4 | 0.066 |
SD standard deviation, CHF congestive heart failure, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, MAP mean arterial pressure, HR heart rate, IQR interquartile rate, APACHE Acute Physiology and Chronic Health Evaluation, [Cl ] initial chloride concentration, [Cl - ] maximal chloride concentration in the first 48 hours, Δ[Cl ] increase in serum chloride; AKI acute kidney injury, RRT renal replacement therapy
aIndicates statistical significance, p < 0.05
Univariate logistic regression model to test association of AKI and initial serum chloride ([CL-]0), maximal serum chloride in first 48 hours ([Cl–]max), and increase in serum chloride (Δ[Cl-] = [Cl-]max–[CL-]0)
| Variable | AKI stage 1 to 3 |
| AKI stage 2 and 3 |
|
|---|---|---|---|---|
| Odds ratio (95 % CI) | Odds ratio (95 % CI) | |||
| [CL-]0 | 1.01 (0.97–1.05) | 0.478 | 0.99 (0.95–1.03) | 0.562 |
| [Cl-]max | 1.14 (1.08–1.20) | <0.001a | 1.07 (1.02–1.12) | 0.006a |
| Δ[CL-] | 1.25 (1.16–1.36) | <0.001a | 1.14 (1.07–1.21) | <0.001a |
AKI acute kidney injury, [Cl ] initial chloride concentration, [Cl ] maximal chloride concentration in the first 48 hours, Δ[Cl ] increase in serum chloride, CI confidence interval
aIndicates statistical significance, p <0.05
Fig. 2Increase in serum chloride and AKI severity. The mean increase in serum chloride (Δ[Cl-]) in AKI stage 1, 2 and 3 is significantly higher than in patients without AKI (p < 0.05) and these data suggest a dose-response relationship between Δ[Cl-] and AKI stage. Δ[Cl ] increase in serum chloride, AKI acute kidney injury,
Univariate logistic regression model to test association of AKI and increase in serum chloride (ΔCL = [Cl-]max - CL0) in all patients and patients without hyperchloremia
| Variable | AKI stage 1 to 3 |
| AKI stage 2 and 3 |
|
|---|---|---|---|---|
| Odds ratio (95 % CI) | Odds ratio (95 % CI) | |||
| All patients | ||||
| Δ[Cl-] | 1.25 (1.16–1.36) | <0.001a | 1.14 (1.07–1.20) | <0.001a |
| Δ[Cl-] ≥ 5 mmol/l | 5.70 (3.00–10.82) | <0.001a | 3.40 (1.95–5.94) | <0.001a |
| Patients without hyperchloremia | ||||
| Δ[Cl-] | 1.37 (1.20–1.56) | <0.001a | 1.25 (1.13–1.38) | <0.001a |
| Δ[Cl-] ≥ 5 mmol/l | 8.25 (3.44–19.78) | <0.001a | 4.77 (2.13–10.70) | <0.001a |
AKI acute kidney injury, Δ[Cl ] increase in serum chloride, [Cl ] maximal chloride concentration in the first 48 hours, [Cl ] initial chloride concentration, CI confidence interval
aIndicates statistical significance, p < 0.05
Multivariate logistic regression of association of AKI with initial serum chloride ([Cl-]0), maximal serum chloride ([Cl-]max), initial serum sodium (Na0) and maximal serum sodium(Namax)
| OR | 95 % confidence interval |
| ||
|---|---|---|---|---|
| Age | 0.99 | 0.95 | 1.04 | 0.776 |
| Sex (male) | 0.40 | 0.09 | 1.77 | 0.228 |
| Hypertension | 0.68 | 0.13 | 3.70 | 0.656 |
| APACHE II | 1.55 | 1.19 | 2.03 | 0.001a |
| Serum lactate | 1.60 | 0.84 | 3.04 | 0.155 |
| Norepinephrine dosage | 1.06 | 0.82 | 1.36 | 0.680 |
| Ventilator requirement | 3.95 | 0.57 | 27.44 | 0.165 |
| [Cl-]0 | 0.87 | 0.70 | 1.10 | 0.240 |
| [Cl-]max | 1.28 | 1.02 | 1.62 | 0.037a |
| Δ[Cl-] | 1.32 | 1.07 | 1.61 | 0.008a |
| Na0 | 1.01 | 0.76 | 1.35 | 0.825 |
| Namax | 1.03 | 0.81 | 1.31 | 0.825 |
Multivariate logistic regression model was adjusted by incorporating all potentially confounding factors including age, gender, underlying diseases, initial serum lactate, APACHE II score and requirement of vasopressor and ventilator
AKI acute kidney injury, OR odds ratio, APACHE Acute Physiology and Chronic Health Evaluation
aIndicates statistical significance, p < 0.05